<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098768</article-id><article-id pub-id-type="doi">10.7759/cureus.82770</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group><subj-group><subject>Oncology</subject></subj-group></article-categories><title-group><article-title>Therapeutic Drug-Drug Interactions (DDIs) Causing QT Prolongation in Patients With Cancer: A Systematic Review and Meta-Analysis</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ramasubbu</surname><given-names>Saravana Kumar</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Mishra</surname><given-names>Archana</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Mandal</surname><given-names>Soumitra</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>K</surname><given-names>Chandrahasan</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>B M</surname><given-names>Prakash</given-names></name><xref rid="aff-4" ref-type="aff">4</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Department of Pharmacology, Andaman and Nicobar Islands Institute of Medical Sciences, Sri Vijaya Puram, IND </aff><aff id="aff-2">
<label>2</label>
Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, IND </aff><aff id="aff-3">
<label>3</label>
Department of Pharmacology, All India Institute of Medical Sciences, Kalyani, Saguna, IND </aff><aff id="aff-4">
<label>4</label>
Independent Practice, Pharmacology, Mysore, IND </aff><author-notes><corresp id="cor1">
Soumitra Mandal <email>soumitra.habul@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>4</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>4</month><year>2025</year></pub-date><volume>17</volume><issue>4</issue><elocation-id>e82770</elocation-id><history><date date-type="accepted"><day>21</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Ramasubbu et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Ramasubbu et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/336131-therapeutic-drug-drug-interactions-ddis-causing-qt-prolongation-in-patients-with-cancer-a-systematic-review-and-meta-analysis">This article is available from https://www.cureus.com/articles/336131-therapeutic-drug-drug-interactions-ddis-causing-qt-prolongation-in-patients-with-cancer-a-systematic-review-and-meta-analysis</self-uri><abstract><p>Therapeutic drug-drug interactions (DDIs) have the potential to harm the patient by causing serious and unwanted side effects. Patients suffering from cancer are exposed to numerous drugs, such as therapeutic drugs and adjuvant treatments for the comorbidities and the side effects of chemotherapy. The concomitant use of anticancer and adjuvant drugs makes such&#x000a0;patients prone to QT prolongation, which could precipitate torsades de pointes or TdP. The current review aims to summarize the prevalence of therapeutic DDIs causing QT prolongation in these patients. A thorough literature search was performed using databases such as PubMed, Google Scholar, and Research Gate. Medical Subject Headings (MeSH) and alternate search terminologies such as &#x0201c;QT prolongation&#x0201d;, &#x0201c;Drug interactions&#x0201d;, and &#x0201c;Cancer&#x0201d; were used to identify all the relevant articles published in English to date. The data from&#x000a0;all such published articles available on the day of the collection were&#x000a0;considered&#x000a0;and fed into the meta package of R software for measuring the outcomes. The literature search&#x000a0;yielded seven unique and relevant articles, which were&#x000a0;included in our study. In these studies, therapeutic DDIs causing QT prolongation were found to occur in 3558 out of 8013 patients undergoing evaluation. Their&#x000a0;prevalence in patients with cancer was estimated to be 22% with a 95% CI between 4% and 63%. The patient characteristics, such as age, comorbid diseases, drugs for supportive care, and polypharmacy, were identified as risk factors associated with potential DDIs. Our data concluded that 22% of the patients administered anticancer drugs were exposed to concomitant drugs leading to DDIs, which&#x000a0;prolonged the QT interval. Thus, the implementation of vigilant measures and precautionary safety interventions becomes vital to forestall QT prolongation and any other adverse cardiac events in this group of patients.</p></abstract><kwd-group kwd-group-type="author"><kwd>adverse drug reactions</kwd><kwd>cancer patients</kwd><kwd>drug-drug interactions</kwd><kwd>prevalence</kwd><kwd>qt prolongation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction and background</title><p>Introduction</p><p>The possibility of therapeutic drug-drug interactions (DDIs) and their aftereffects is a holy grail in clinical practice, and occurs when two or more drugs are administered concomitantly and one drug influences the effect of the other, leading to decreased efficacy and/or increased side effects [<xref rid="REF1" ref-type="bibr">1</xref>,<xref rid="REF2" ref-type="bibr">2</xref>]. DDIs can harm the patient by causing serious unwanted side effects [<xref rid="REF3" ref-type="bibr">3</xref>]. Patients with cancer are exposed to numerous drugs, which include&#x000a0;drugs to treat the disease, reduce associated pain, and&#x000a0;treat comorbid illnesses (diabetes, hyperlipidemias, and cardiac diseases, etc.), along with adjuvant drugs to combat the adverse effects due to cancer chemotherapy. Exposure to multiple drugs makes these patients vulnerable to potentially serious DDIs, and it can get worse if there is a comorbid illness&#x000a0;(renal failure, liver failure, and heart failure) [<xref rid="REF4" ref-type="bibr">4</xref>].</p><p>The most notable aspect of cardiac rhythm disorders brought on by anticancer medications and supportive care therapy is the prolonged QT interval, which can eventually result in ventricular arrhythmias, especially when these medications are used concurrently. On the electrocardiography (ECG) rhythm strip, the interval between the initiation of the QRS complex and the end of the T wave is measured as the QT interval. It&#x000a0;demonstrates the phases of ventricular depolarization and subsequent repolarization. The rare and deadly polymorphic ventricular tachycardia known as torsades de pointes (TdP) is frequently represented by&#x000a0;twisting of the points on an ECG [<xref rid="REF5" ref-type="bibr">5</xref>,<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>Arsenic trioxide (AsO3), used in the treatment of acute promyelocytic leukemia (APL), when taken at therapeutic doses, may prolong the QT interval and cause TdP [<xref rid="REF7" ref-type="bibr">7</xref>]. Anthracyclines prolong the QT interval by inducing effects on ion channels [<xref rid="REF8" ref-type="bibr">8</xref>]. QT interval changes have also been linked to tamoxifen and its metabolites (4-hydroxytamoxifen), most likely as a result of the human ether-&#x000e0;-go-go-related gene (HERG) potassium channel blockade [<xref rid="REF9" ref-type="bibr">9</xref>]. Both QT interval prolongation and TdP have been linked to platinum compounds, particularly oxaliplatin. By extending the sodium (Na<sup>+</sup>) channel opening, oxaliplatin can enhance Na<sup>+</sup> influx and impact cardiac repolarization [<xref rid="REF10" ref-type="bibr">10</xref>]. A 49-year-old African American man suffering from cutaneous T-cell lymphoma (CTCL) was reported to have developed TdP after receiving the histone deacetylase (HDAC) inhibitor vorinostat for his treatment&#x000a0;[<xref rid="REF11" ref-type="bibr">11</xref>]. Many tyrosine kinase inhibitors, such as crizotinib, ponatinib, nilotinib, cediranib, vandetanib, lapatinib, sunitinib, etc., are associated with QT interval prolongation [<xref rid="REF12" ref-type="bibr">12</xref>].</p><p>Previous studies have attempted to estimate the use of QT-interval-extending drugs and the occurrence of QT&#x000a0;prolongation due to DDIs in patients with cancer. The current study systematically reviews the possibility of DDIs in patients with cancer and the&#x000a0;associated risk factors, and provides a quantitative estimate of their pooled prevalence.</p></sec><sec sec-type="review"><title>Review</title><p>Methodology</p><p>Study Protocol</p><p>The meta-analysis of observational studies in epidemiology (MOOSE) was employed to perform this review and meta-analysis [<xref rid="REF13" ref-type="bibr">13</xref>]. The protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) vide reference ID number: CRD42023409522.</p><p>Purpose</p><p>To estimate the prevalence of therapeutic DDIs causing QT prolongation in patients with cancer. Hence, our P - Population, I - Intervention, C - Comparison, O - Outcome, or PICO elements were P: Cancer patients; I: DDIs causing QT Prolongation; C: not applicable; and O: Potential DDIs.</p><p>Inclusion and Exclusion Criteria</p><p>The published articles included were observational studies with prospective, retrospective, and cross-sectional study designs reporting the prevalence of DDIs causing QT prolongation in patients diagnosed with cancer who were on chemotherapy. There was no time limit specified. Articles not published in English and&#x000a0;those without sufficient data for analysis were excluded.</p><p>Data Extraction</p><p>The authors developed a standard data extraction sheet in Microsoft Excel (Microsoft Corp., Redmond, WA, US). The data significant to the study, such as the design used,&#x000a0;the study setting, target population, total number of patients with cancer, total number of patients with potential QT-interval prolonging DDIs, author details, month and year of publication, and a comprehensive list of drug classes that may potentially cause DDIs were extracted. The desired outcome, such as the percentage of QT-prolonging DDIs&#x000a0;and the associated risk factors was also extracted.</p><p>Quality Assessment&#x000a0;</p><p>The quality of the articles&#x000a0;was assessed using the 12-point criteria adopted from a prior study, Nabovati et al., 2014 [<xref rid="REF14" ref-type="bibr">14</xref>]. The&#x000a0;points&#x000a0;assessed included the study's objectives, data collection methodology, study setting, inclusion/exclusion criteria, the definition of a DDI and its&#x000a0;categories, the DDI categories considered, and reference to a DDI. The sampling population and sample size calculation, potential or actual DDIs evaluated, quality control, and the study limitations listed were also evaluated. The quality assessment was based on the criterion scores of 0 or 1, with total scores ranging from 0 to 12 (scores 0 to 6 indicated poor quality, 7 to 9 indicated moderate quality, and 10 to 12 indicated high quality) (Table <xref rid="TAB1" ref-type="table">1</xref>).&#x000a0;</p><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Quality assessment of the included studies</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Studies</td><td rowspan="1" colspan="1">Total score</td><td rowspan="1" colspan="1">Quality</td></tr><tr><td rowspan="1" colspan="1">Agnihotri et al. (2024) [<xref rid="REF15" ref-type="bibr">15</xref>]</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">Moderate</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Balk et al. (2017) [<xref rid="REF16" ref-type="bibr">16</xref>]</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">Fort et al. (2022) [<xref rid="REF17" ref-type="bibr">17</xref>]</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Poor</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Hussaarts et al. (2019) [<xref rid="REF18" ref-type="bibr">18</xref>]</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Poor</td></tr><tr><td rowspan="1" colspan="1">Khan et al. (2017) [<xref rid="REF19" ref-type="bibr">19</xref>]&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">Moderate</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Kim et al. (2019) [<xref rid="REF20" ref-type="bibr">20</xref>]</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">Ramasubbu et al. (2021) [<xref rid="REF21" ref-type="bibr">21</xref>]</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">Moderate</td></tr></tbody></table></table-wrap><p>Outcome measurements</p><p>The primary goal was to determine the collective estimate of the DDIs leading to prolongation of the QT interval in patients with cancer. The secondary goal was to determine potential risk factors for the DDIs that cause this QT prolongation.</p><p>Data analysis</p><p>The pooled estimate of prevalence, i.e., the prevalence of DDIs causing QT prolongation, and subgroup analysis were done by the meta package in R software (R Development Core Team,&#x000a0;Vienna, Austria). In this review, the random-effects model was taken into consideration to estimate the clinical heterogeneity among studies.&#x000a0;</p><p>Search strategy</p><p>A thorough literature search was performed using databases such as PubMed, Google Scholar, and Research Gate with carefully chosen Medical Subject Headings (MeSH) terms (Appendix). There were 82 articles identified through this search. After the removal of duplicates, 37 unique articles were subjected to an initial screening, out of which 25 were rejected as they were deemed irrelevant&#x000a0;to the current study. Five manuscripts were&#x000a0;eliminated because of insufficient data or missing outcome variables. The final outcome yielded seven articles for our&#x000a0;assessment and analysis&#x000a0;(Figure <xref rid="FIG1" ref-type="fig">1</xref>).</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>PRISMA flow diagram of the study screening and selection</title><p>PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis [<xref rid="REF22" ref-type="bibr">22</xref>]</p></caption><graphic xlink:href="cureus-0017-00000082770-i01" position="float"/></fig><p>General characteristics of the included studies</p><p>Seven unique, relevant, and full-text articles were included in the current study [<xref rid="REF15" ref-type="bibr">15</xref>-<xref rid="REF21" ref-type="bibr">21</xref>]. Their important characteristics are&#x000a0;presented in Table <xref rid="TAB2" ref-type="table">2</xref>. The study designs of the included articles were cross-sectional, prospective, and retrospectively observational. The year of publication ranged from 2017 to 2024. The studies included patients with cancer treated in out-patient and in-patient settings. Six different evidence-based medicine tools were used to detect potential DDIs in these&#x000a0;studies.</p><table-wrap position="float" id="TAB2"><label>Table 2</label><caption><title>General characteristics of the studies included in the systematic review and meta-analysis</title><p>OPD, out-patient department; IPD, in-patient department; CS, cross-sectional;&#x000a0;OS, Observational study; NR, not reported</p><p>*potential or clinically-relevant</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Author (Year)</td><td rowspan="1" colspan="1">Setting</td><td rowspan="1" colspan="1">Design</td><td rowspan="1" colspan="1">Methods of DDI detection&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</td><td rowspan="1" colspan="1">Types of DDIs* causing the QT prolongation assessed</td><td rowspan="1" colspan="1">Quality of the study included</td><td rowspan="1" colspan="1">Specific drugs used</td><td rowspan="1" colspan="1">Measures taken for the DDIs causing QT prolongation</td></tr><tr><td rowspan="1" colspan="1">Agnihotri et al. (2024) [<xref rid="REF15" ref-type="bibr">15</xref>] &#x000a0;</td><td rowspan="1" colspan="1">OPD</td><td rowspan="1" colspan="1">CS</td><td rowspan="1" colspan="1">
<ext-link xlink:href="https://Drugs.com" ext-link-type="uri">Drugs.com</ext-link>, Epocrates, Medscape &#x000a0;</td><td rowspan="1" colspan="1">Potential</td><td rowspan="1" colspan="1">Moderate &#x000a0;</td><td rowspan="1" colspan="1">Capecitabine, Oxaliplatin, Bortezomib, Bendamustine, Domperidone, Ondansetron, Olanzapine, Tramadol</td><td rowspan="1" colspan="1">NR</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Balk et al. (2017) [<xref rid="REF16" ref-type="bibr">16</xref>] &#x000a0;</td><td rowspan="1" colspan="1">OPD</td><td rowspan="1" colspan="1">Prospective OS</td><td rowspan="1" colspan="1">Micromedex solutions, Dutch drug database &#x000a0;</td><td rowspan="1" colspan="1">Potential</td><td rowspan="1" colspan="1">Moderate &#x000a0;</td><td rowspan="1" colspan="1">Ciprofloxacin, Methotrexate, Cotrimoxazole, Vincristine, Itraconazole, Aprepitant</td><td rowspan="1" colspan="1">ECG monitoring was advised to the treating oncologist</td></tr><tr><td rowspan="1" colspan="1">Fort et al. (2022) [<xref rid="REF17" ref-type="bibr">17</xref>] &#x000a0;</td><td rowspan="1" colspan="1">OPD &#x00026; IPD</td><td rowspan="1" colspan="1">Prospective OS</td><td rowspan="1" colspan="1">Micromedex &#x000a0;</td><td rowspan="1" colspan="1">Potential</td><td rowspan="1" colspan="1">Poor</td><td rowspan="1" colspan="1">Sunitinib, Osimertinib, Cabozantinib, Citalopram, Quetiapine, Tramadol</td><td rowspan="1" colspan="1">NR</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Hussaarts et al. (2019) [<xref rid="REF18" ref-type="bibr">18</xref>]</td><td rowspan="1" colspan="1">OPD &#x00026; IPD</td><td rowspan="1" colspan="1">Retrospective OS</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Potential and clinically relevant</td><td rowspan="1" colspan="1">Poor</td><td rowspan="1" colspan="1">Tamoxifen, Selective Serotonin Reuptake Inhibitors (SSRIs)</td><td rowspan="1" colspan="1">Baseline and follow up ECG was done</td></tr><tr><td rowspan="1" colspan="1">Khan et al. (2017) [<xref rid="REF19" ref-type="bibr">19</xref>] &#x000a0;</td><td rowspan="1" colspan="1">OPD &#x00026; IPD</td><td rowspan="1" colspan="1">CS</td><td rowspan="1" colspan="1">Micromedex &#x000a0;</td><td rowspan="1" colspan="1">Potential</td><td rowspan="1" colspan="1">Moderate &#x000a0;</td><td rowspan="1" colspan="1">Ciprofloxacin, Ondansteron, Prochlorperazine, Metronidazole, Dolosetron, Nilotinib</td><td rowspan="1" colspan="1">NR</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Kim et al. (2019) [<xref rid="REF20" ref-type="bibr">20</xref>] &#x000a0;</td><td rowspan="1" colspan="1">OPD &#x00026; IPD</td><td rowspan="1" colspan="1">Retrospective OS</td><td rowspan="1" colspan="1">Lexicomp, Micromedex &#x000a0;</td><td rowspan="1" colspan="1">Potential</td><td rowspan="1" colspan="1">Moderate &#x000a0;</td><td rowspan="1" colspan="1">Tamoxifen, Clarithromycin, Nilotinib, Imatinib, Domperidone</td><td rowspan="1" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Ramasubbu et al. (2021) [<xref rid="REF21" ref-type="bibr">21</xref>] &#x000a0;</td><td rowspan="1" colspan="1">OPD &#x00026; IPD</td><td rowspan="1" colspan="1">CS</td><td rowspan="1" colspan="1">
<ext-link xlink:href="https://Drugs.com" ext-link-type="uri">Drugs.com</ext-link>, Epocrates, Medscape &#x000a0;</td><td rowspan="1" colspan="1">Potential</td><td rowspan="1" colspan="1">Moderate &#x000a0;</td><td rowspan="1" colspan="1">Oxaliplatin, Ondansetron, Tramadol, Epirubicin, Fluconazole, Hydrochlorthiazide, Pantoprazole</td><td rowspan="1" colspan="1">NR</td></tr></tbody></table></table-wrap><p>Prevalence of DDIs causing QT prolongation</p><p>The data on DDIs causing QT prolongation are presented in Table <xref rid="TAB3" ref-type="table">3</xref>.</p><table-wrap position="float" id="TAB3"><label>Table 3</label><caption><title>Prevalence of DDIs causing QT prolongation in the articles evaluated</title><p>DDI, drug-drug interaction</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Study</td><td rowspan="1" colspan="1">Total no. of patients</td><td rowspan="1" colspan="1">No. of patients with DDIs causing QT prolongation</td><td rowspan="1" colspan="1">Prevalence of DDIs causing QT prolongation (%)</td></tr><tr><td rowspan="1" colspan="1">Agnihotri et al. (2024) [<xref rid="REF15" ref-type="bibr">15</xref>]</td><td rowspan="1" colspan="1">1331</td><td rowspan="1" colspan="1">1295</td><td rowspan="1" colspan="1">97.2</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Balk et al. (2017) [<xref rid="REF16" ref-type="bibr">16</xref>] &#x000a0;</td><td rowspan="1" colspan="1">73</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2.73</td></tr><tr><td rowspan="1" colspan="1">Fort et al. (2022) [<xref rid="REF17" ref-type="bibr">17</xref>] &#x000a0;</td><td rowspan="1" colspan="1">171</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">21.63</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Hussaarts et al. (2019) [<xref rid="REF18" ref-type="bibr">18</xref>]</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Khan et al. (2017) [<xref rid="REF19" ref-type="bibr">19</xref>] &#x000a0;</td><td rowspan="1" colspan="1">555</td><td rowspan="1" colspan="1">121</td><td rowspan="1" colspan="1">21.80</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Kim et al. (2019) [<xref rid="REF20" ref-type="bibr">20</xref>] &#x000a0;</td><td rowspan="1" colspan="1">5657</td><td rowspan="1" colspan="1">2075</td><td rowspan="1" colspan="1">36.68</td></tr><tr><td rowspan="1" colspan="1">Ramasubbu et al. (2021) [<xref rid="REF21" ref-type="bibr">21</xref>]</td><td rowspan="1" colspan="1">126</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">21.42</td></tr></tbody></table></table-wrap><p>The pooled prevalence of DDIs causing QT prolongation in patients with cancer included in the seven studies was estimated to be 22% with a 95% CI between 4% and 63% (Figure <xref rid="FIG2" ref-type="fig">2</xref>). The heterogeneity across the studies was estimated to be high (I&#x000b2; = 99%, p&#x0003c;0.01).</p><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title>Forest plot depicting the pooled prevalence of DDIs causing QT prolongation in patients with cancer</title><p>Citations for the included studies [<xref rid="REF15" ref-type="bibr">15</xref>-<xref rid="REF21" ref-type="bibr">21</xref>]; DDI, drug-drug interaction</p></caption><graphic xlink:href="cureus-0017-00000082770-i02" position="float"/></fig><p>Subgroup analysis</p><p>A subgroup analysis performed to compare the study designs of the included studies&#x000a0;found that there was no difference between the study design and the occurrence of DDIs causing QT prolongation in&#x000a0;patients with cancer (Figure <xref rid="FIG3" ref-type="fig">3</xref>).</p><fig position="anchor" fig-type="figure" id="FIG3"><label>Figure 3</label><caption><title>Forest plot comparing the study designs of the studies included in the analysis</title><p>Citations for included studies [<xref rid="REF15" ref-type="bibr">15</xref>-<xref rid="REF21" ref-type="bibr">21</xref>]</p></caption><graphic xlink:href="cureus-0017-00000082770-i03" position="float"/></fig><p>Risk factors associated with the DDIs causing QT prolongation</p><p>Factors such as polypharmacy, comorbidities, use of supportive care therapy, and advanced age&#x000a0;increased the risk of DDIs causing QT prolongation in&#x000a0;patients with cancer (Table <xref rid="TAB4" ref-type="table">4</xref>).</p><table-wrap position="float" id="TAB4"><label>Table 4</label><caption><title>Associated risk factors for DDIs causing QT prolongation</title><p>DDI, drug-drug interaction</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Factors that increase the risk of DDIs causing QT prolongation</td><td rowspan="1" colspan="1">Description</td></tr><tr><td rowspan="1" colspan="1">Polypharmacy</td><td rowspan="1" colspan="1">Increase in the number and concomitant use of many drugs</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Comorbid diseases</td><td rowspan="1" colspan="1">Presence of comorbid diseases like diabetes may elevate the risk</td></tr><tr><td rowspan="1" colspan="1">Use of supportive care drugs</td><td rowspan="1" colspan="1">Use of multiple drugs for supportive care along with cancer chemotherapy can predispose the patients</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">Elderly patients were found to be more predisposed</td></tr></tbody></table></table-wrap><p>Discussion</p><p>This systematic review and meta-analysis on the therapeutic DDIs causing QT prolongation in patients with cancer studied the prevalence of such DDIs&#x000a0;and their associated risk factors. Data from 8013 patients were included in our analysis to uncover the pooled estimate of the primary outcome. The overall prevalence of DDIs causing QT prolongation in patients with cancer in our study was 22% (4%-63%; 95% CI).</p><p>Moghaddas et al. (2021) evaluated therapeutic DDIs&#x000a0;in hospitalized patients with cancer&#x000a0;and reported that&#x000a0;80.8% of them were exposed to DDIs, which is higher than our&#x000a0;study [<xref rid="REF23" ref-type="bibr">23</xref>]. Another study by Girre et al. (2019)&#x000a0;reported that 30.4% of elderly&#x000a0;patients with cancer were at risk of DDIs, which is also slightly higher than the present&#x000a0;study [<xref rid="REF24" ref-type="bibr">24</xref>]. These differences could be explained by the various classification schemes used. Studies have shown that healthcare providers may become confused about how to handle the DDIs&#x000a0;due to their inconsistent classifications and the information provided by different sources that detail DDIs.</p><p>In one of the evaluated studies, the potential DDI&#x000a0;was extracted and presented to a committee of experts. After the consensus, if the DDI required intervention, the treating oncologist was informed and advised on how to manage it [<xref rid="REF16" ref-type="bibr">16</xref>]. In another study conducted on patients with breast cancer treated with tamoxifen and selective serotonin reuptake inhibitor (SSRIs),&#x000a0;an ECG was performed to measure the QT interval at baseline and during&#x000a0;follow-up [<xref rid="REF18" ref-type="bibr">18</xref>]. Agnihotri et al. (2024) [<xref rid="REF15" ref-type="bibr">15</xref>] estimated that 97.2% of the patients were at risk of potential DDIs causing QT prolongation. This finding is in contrast to a study by Hussaarts et al. (2019) [<xref rid="REF18" ref-type="bibr">18</xref>], where the prevalence was only 1%. This difference in findings may be attributed to the difference in the sensitivity of the software used to detect the DDIs. No&#x000a0;DDI database software offers 100% sensitivity or specificity when&#x000a0;evaluating them. Notably, there are discrepancies in the grading of severity in this type&#x000a0;of software, which poses a challenge to the treating oncologist when they encounter potential DDIs. These inconsistent results could also be caused by differences in the patients' clinical profiles and the prescribing patterns of physicians. Decisions to enforce preventive strategies to combat DDIs causing QT prolongation should not be solely based on potential DDIs causing QT prolongation, as the significant difference in prevalence rates indicates that they are poor predictors of harm caused to the patient.</p><p>Polypharmacy can potentiate the risk of DDIs in patients with cancer. Prescribing combinations of anticancer drugs along with drugs for supportive care&#x000a0;and concurrent use of other QT-prolonging drugs can heighten the risk of QT prolongation. Studies&#x000a0;in elderly patients with cancer show that the prevalence rate of polypharmacy ranges from 2% to 80%, depending upon the population studied and the definition of polypharmacy [<xref rid="REF25" ref-type="bibr">25</xref>].&#x000a0;A case report by Cerd&#x000e0; et al. showed that a patient on chemotherapy was prescribed a combination of methadone, haloperidol, and fluoxetine. Subsequently, the patient developed cardiac adverse events, presented&#x000a0;with chest pain and bradycardia, and was diagnosed with reversible QT prolongation. It shows that polypharmacy can lead to QT prolongation in such patients [<xref rid="REF26" ref-type="bibr">26</xref>]. Physicians who prescribe anticancer and supportive care medications to&#x000a0;patients with cancer&#x000a0;should carefully consider the risk factors for QT prolongation.</p><p>The presence of comorbid illness also increases the risk of QT prolongation in patients with cancer. Electrolyte imbalances and the therapeutic use of diuretics are two additional risk factors that increase the risk of TdP [<xref rid="REF21" ref-type="bibr">21</xref>]. Prolonged proton pump inhibitor use&#x000a0;can result in hypomagnesemia and its major complications, such as QT prolongation and potentially fatal ventricular arrhythmias [<xref rid="REF27" ref-type="bibr">27</xref>]. Similarly, prolonged QT interval and hypokalemia are adverse effects&#x000a0;attributed to 5-hydroxytryptamine type 3 receptor (5HT-3) antagonists&#x000a0;such as ondansetron, which is a commonly used&#x000a0;anti-emetic. Additionally, one of the modifiable risk factors for drug-induced TdP is hypokalemia [<xref rid="REF28" ref-type="bibr">28</xref>].&#x000a0;This study will provide physicians with valuable information on the risks of DDIs causing QT prolongation, an area where data is currently limited.</p><p>Recommendations</p><p>The following measures can be adopted by the clinician to prevent QT prolongation in patients with cancer. First, address the electrolyte abnormalities by supplementing and maintaining potassium and magnesium levels during chemotherapy. Second, discontinue the use of diuretics as much as possible. Third, identify&#x000a0;concomitant drugs that can increase the QT interval. Clinicians should discontinue the offending drug or use an alternative drug that has no impact on the QT interval. Fourth, conduct a&#x000a0;risk-benefit analysis to determine the use of an alternative antineoplastic agent. Fifth, before beginning treatment, obtain a baseline ECG&#x000a0;to identify any patients who may be predisposed to a prolonged QT&#x000a0;interval [<xref rid="REF29" ref-type="bibr">29</xref>]. Finally, examine the potential DDIs of prescribed medications using a variety of online DDI checking tools and make the necessary adjustments. Physicians need to inform patients and make them aware of the potential risks associated with self-medication as well as the likely hazards of DDIs&#x000a0;[<xref rid="REF21" ref-type="bibr">21</xref>].</p><p>Future direction</p><p>There is currently no clear guideline for assessing DDIs associated with multiple drugs that cause QT prolongation. This topic should be the focus of future research.</p><p>Limitations</p><p>Only one study in this meta-analysis had&#x000a0;ECG data pertaining to QT prolongation.&#x000a0;There may be inconsistencies in the software used to detect the DDIs.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The prevalence of potential DDIs causing QT prolongation was estimated to be 22% in patients with cancer undergoing treatment. The associated risk factors were old age, polypharmacy, use of drugs for supportive care, and comorbid conditions. Geriatric patients with cancer are at a high risk of developing DDIs with QT prolongation due to polypharmacy. We recommend&#x000a0;incorporating QT prolongation and the risk of TdP into patient monitoring plans in clinical practice. It is imperative to adopt precautionary measures to forestall QT prolongation in elderly&#x000a0;patients with cancer. The treating physician can identify possible DDIs and make appropriate modifications to the treatment plan by using the online DDI checking software. To optimize drug therapy in patients with cancer, an integrative and algorithmic approach involving general practitioners, cardiologists, oncologists, and clinical pharmacologists/pharmacists is necessary.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Soumitra Mandal, Saravana Kumar Ramasubbu, Archana Mishra, Chandrahasan K, Prakash B M</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Soumitra Mandal, Saravana Kumar Ramasubbu, Archana Mishra, Chandrahasan K, Prakash B M</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Soumitra Mandal, Saravana Kumar Ramasubbu, Archana Mishra, Chandrahasan K, Prakash B M</p><p><bold>Supervision:</bold>&#x000a0; Soumitra Mandal, Saravana Kumar Ramasubbu, Prakash B M</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Saravana Kumar Ramasubbu, Archana Mishra, Chandrahasan K, Prakash B M</p></fn></fn-group><app-group><app><title>Appendices</title><table-wrap position="anchor" id="TAB5"><label>Table 5</label><caption><title>Data sources and literature search strategy</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">A thorough literature search was performed using databases such as PubMed, Embase, and Research Gate with carefully chosen words, namely &#x0201c;Prevalence&#x0201d;, &#x0201c;QT-prolongation&#x0201d;, &#x0201c;DDIs&#x0201d;, &#x0201c;associated factors&#x0201d;, &#x0201c;cancer&#x0201d;, and &#x0201c;oncology&#x0201d;. AND/OR Boolean operators were used for narrowing down the search in the identification of the relevant articles. The key words used in PubMed were ("epidemiology"[MeSH Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR "prevalence"[MeSH Terms] OR "prevalance"[All Fields] OR "prevalences"[All Fields] OR "prevalence s"[All Fields] OR "prevalent"[All Fields] OR "prevalently"[All Fields] OR "prevalents"[All Fields]) AND ("QT"[All Fields] AND ("interval"[All Fields] OR "intervals"[All Fields])) AND ("drug interactions"[MeSH Terms] OR ("drug"[All Fields] AND "interactions"[All Fields]) OR "drug interactions"[All Fields] OR ("drug"[All Fields] AND "interaction"[All Fields]) OR "drug drug interaction"[All Fields]) AND (("cancer s"[All Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR "cancers"[All Fields]) AND ("patient s"[All Fields] OR "patients"[MeSH Terms] OR "patients"[All Fields] OR "patient"[All Fields] OR "patients s"[All Fields])). All research articles published till &#x02018;June 2024&#x02019; and which met the inclusion criteria were taken into account. &#x000a0;</td></tr></tbody></table></table-wrap></app></app-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Stockley's Drug Interactions. Tenth edition, Stockley's Drug Interactions Pocket Companion 2013</article-title><source>J Med Libr Assoc</source><person-group>
<name><surname>Adams</surname><given-names>CD</given-names></name>
</person-group><fpage>221</fpage><volume>102</volume><year>2014</year></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico</article-title><source>PLoS One</source><person-group>
<name><surname>Morales-R&#x000ed;os</surname><given-names>O</given-names></name>
<name><surname>Jasso-Guti&#x000e9;rrez</surname><given-names>L</given-names></name>
<name><surname>Reyes-L&#x000f3;pez</surname><given-names>A</given-names></name>
<name><surname>Gardu&#x000f1;o-Espinosa</surname><given-names>J</given-names></name>
<name><surname>Mu&#x000f1;oz-Hern&#x000e1;ndez</surname><given-names>O</given-names></name>
</person-group><fpage>0</fpage><volume>13</volume><year>2018</year></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Adverse drug events associated with hospital admission</article-title><source>Ann Pharmacother</source><person-group>
<name><surname>Peyriere</surname><given-names>H</given-names></name>
<name><surname>Cassan</surname><given-names>S</given-names></name>
<name><surname>Floutard</surname><given-names>E</given-names></name>
<etal/>
</person-group><fpage>5</fpage><lpage>11</lpage><volume>37</volume><year>2003</year><pub-id pub-id-type="pmid">12503925</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Cardiotoxicity of antiemetic drugs in oncology: an overview of the current state of the art</article-title><source>Crit Rev Oncol Hematol</source><person-group>
<name><surname>Barni</surname><given-names>S</given-names></name>
<name><surname>Petrelli</surname><given-names>F</given-names></name>
<name><surname>Cabiddu</surname><given-names>M</given-names></name>
</person-group><fpage>125</fpage><lpage>134</lpage><volume>102</volume><year>2016</year><pub-id pub-id-type="pmid">27143244</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Drugs, QT interval prolongation and ICH E14: the need to get it right</article-title><source>Drug Saf</source><person-group>
<name><surname>Shah</surname><given-names>RR</given-names></name>
</person-group><fpage>115</fpage><lpage>125</lpage><volume>28</volume><year>2005</year><pub-id pub-id-type="pmid">15691222</pub-id>
</element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead</article-title><source>Drug Saf</source><person-group>
<name><surname>Shah</surname><given-names>RR</given-names></name>
</person-group><fpage>1009</fpage><lpage>1028</lpage><volume>28</volume><year>2005</year><pub-id pub-id-type="pmid">16231954</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives</article-title><source>Oncotarget</source><person-group>
<name><surname>Duan</surname><given-names>J</given-names></name>
<name><surname>Tao</surname><given-names>J</given-names></name>
<name><surname>Zhai</surname><given-names>M</given-names></name>
<etal/>
</person-group><fpage>25738</fpage><lpage>25749</lpage><volume>9</volume><year>2018</year><pub-id pub-id-type="pmid">29876021</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron</article-title><source>Pharmacol Rep</source><person-group>
<name><surname>Sim&#x0016f;nek</surname><given-names>T</given-names></name>
<name><surname>St&#x000e9;rba</surname><given-names>M</given-names></name>
<name><surname>Popelov&#x000e1;</surname><given-names>O</given-names></name>
<name><surname>Adamcov&#x000e1;</surname><given-names>M</given-names></name>
<name><surname>Hrdina</surname><given-names>R</given-names></name>
<name><surname>Gersl</surname><given-names>V</given-names></name>
</person-group><fpage>154</fpage><lpage>171</lpage><volume>61</volume><year>2009</year><pub-id pub-id-type="pmid">19307704</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen</article-title><source>Naunyn Schmiedebergs Arch Pharmacol</source><person-group>
<name><surname>Thomas</surname><given-names>D</given-names></name>
<name><surname>Gut</surname><given-names>B</given-names></name>
<name><surname>Karsai</surname><given-names>S</given-names></name>
<etal/>
</person-group><fpage>41</fpage><lpage>48</lpage><volume>368</volume><year>2003</year><pub-id pub-id-type="pmid">12827215</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons</article-title><source>Eur J Pharmacol</source><person-group>
<name><surname>Adelsberger</surname><given-names>H</given-names></name>
<name><surname>Quasthoff</surname><given-names>S</given-names></name>
<name><surname>Grosskreutz</surname><given-names>J</given-names></name>
<name><surname>Lepier</surname><given-names>A</given-names></name>
<name><surname>Eckel</surname><given-names>F</given-names></name>
<name><surname>Lersch</surname><given-names>C</given-names></name>
</person-group><fpage>25</fpage><lpage>32</lpage><volume>6</volume><year>2000</year></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature</article-title><source>Cardiol J</source><person-group>
<name><surname>Lynch</surname><given-names>DR</given-names></name>
<name><surname>Washam</surname><given-names>JB</given-names></name>
<name><surname>Newby</surname><given-names>LK</given-names></name>
</person-group><fpage>434</fpage><lpage>438</lpage><volume>19</volume><year>2012</year><uri xlink:href="https://journals.viamedica.pl/cardiology_journal/article/view/22992/18227">https://journals.viamedica.pl/cardiology_journal/article/view/22992/18227</uri><pub-id pub-id-type="pmid">22825908</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Cardiovascular toxic effects of targeted cancer therapies</article-title><source>N Engl J Med</source><person-group>
<name><surname>Moslehi</surname><given-names>JJ</given-names></name>
</person-group><fpage>1457</fpage><lpage>1467</lpage><volume>375</volume><year>2016</year><pub-id pub-id-type="pmid">27732808</pub-id>
</element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>MOOSE reporting guidelines for meta-analyses of observational studies</article-title><source>JAMA Surg</source><person-group>
<name><surname>Brooke</surname><given-names>BS</given-names></name>
<name><surname>Schwartz</surname><given-names>TA</given-names></name>
<name><surname>Pawlik</surname><given-names>TM</given-names></name>
</person-group><fpage>787</fpage><lpage>788</lpage><volume>156</volume><year>2021</year><pub-id pub-id-type="pmid">33825847</pub-id>
</element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Drug-drug interactions in inpatient and outpatient settings in Iran: a systematic review of the literature</article-title><source>Daru</source><person-group>
<name><surname>Nabovati</surname><given-names>E</given-names></name>
<name><surname>Vakili-Arki</surname><given-names>H</given-names></name>
<name><surname>Taherzadeh</surname><given-names>Z</given-names></name>
<name><surname>Hasibian</surname><given-names>MR</given-names></name>
<name><surname>Abu-Hanna</surname><given-names>A</given-names></name>
<name><surname>Eslami</surname><given-names>S</given-names></name>
</person-group><fpage>52</fpage><volume>22</volume><year>2014</year><pub-id pub-id-type="pmid">24965959</pub-id>
</element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Prevalence, attributes, and risk factors of QT-interval-prolonging drugs and potential drug-drug interactions in cancer patients: a prospective study in a tertiary care hospital</article-title><source>Cureus</source><person-group>
<name><surname>Agnihotri</surname><given-names>A</given-names></name>
<name><surname>Ramasubbu</surname><given-names>SK</given-names></name>
<name><surname>Bandyopadhyay</surname><given-names>A</given-names></name>
<name><surname>Bidarolli</surname><given-names>M</given-names></name>
<name><surname>Nath</surname><given-names>UK</given-names></name>
<name><surname>Das</surname><given-names>B</given-names></name>
</person-group><fpage>0</fpage><volume>16</volume><year>2024</year></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Drug-drug interactions in pediatric oncology patients</article-title><source>Pediatr Blood Cancer</source><person-group>
<name><surname>Balk</surname><given-names>TE</given-names></name>
<name><surname>van der Sijs</surname><given-names>IH</given-names></name>
<name><surname>van Gelder</surname><given-names>T</given-names></name>
<name><surname>Janssen</surname><given-names>JJ</given-names></name>
<name><surname>van der Sluis</surname><given-names>IM</given-names></name>
<name><surname>van Leeuwen</surname><given-names>RW</given-names></name>
<name><surname>Engels</surname><given-names>FK</given-names></name>
</person-group><volume>64</volume><year>2017</year></element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient</article-title><source>Eur Heart J</source><person-group>
<name><surname>Fort</surname><given-names>E</given-names></name>
<name><surname>Otero</surname><given-names>S</given-names></name>
<name><surname>Moliner</surname><given-names>P</given-names></name>
<etal/>
</person-group><fpage>2726</fpage><volume>43</volume><year>2022</year></element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>The risk of QTc-interval prolongation in breast cancer patients treated with tamoxifen in combination with serotonin reuptake inhibitors</article-title><source>Pharm Res</source><person-group>
<name><surname>Hussaarts</surname><given-names>KG</given-names></name>
<name><surname>Berger</surname><given-names>FA</given-names></name>
<name><surname>Binkhorst</surname><given-names>L</given-names></name>
<etal/>
</person-group><fpage>7</fpage><volume>37</volume><year>2019</year><pub-id pub-id-type="pmid">31845095</pub-id>
</element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study</article-title><source>BMC Pharmacol Toxicol</source><person-group>
<name><surname>Khan</surname><given-names>Q</given-names></name>
<name><surname>Ismail</surname><given-names>M</given-names></name>
<name><surname>Khan</surname><given-names>S</given-names></name>
</person-group><fpage>75</fpage><volume>18</volume><year>2017</year><pub-id pub-id-type="pmid">29191244</pub-id>
</element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study</article-title><source>Support Care Cancer</source><person-group>
<name><surname>Kim</surname><given-names>SH</given-names></name>
<name><surname>Suh</surname><given-names>Y</given-names></name>
<name><surname>Ah</surname><given-names>YM</given-names></name>
<name><surname>Jun</surname><given-names>K</given-names></name>
<name><surname>Lee</surname><given-names>JY</given-names></name>
</person-group><fpage>3617</fpage><lpage>3626</lpage><volume>28</volume><year>2020</year><pub-id pub-id-type="pmid">31802250</pub-id>
</element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: a prospective study in a tertiary care teaching hospital</article-title><source>Cancer Treat Res Commun</source><person-group>
<name><surname>Ramasubbu</surname><given-names>SK</given-names></name>
<name><surname>Mahato</surname><given-names>SK</given-names></name>
<name><surname>Agnihotri</surname><given-names>A</given-names></name>
<name><surname>Pasricha</surname><given-names>RK</given-names></name>
<name><surname>Nath</surname><given-names>UK</given-names></name>
<name><surname>Das</surname><given-names>B</given-names></name>
</person-group><fpage>100277</fpage><volume>26</volume><year>2021</year><pub-id pub-id-type="pmid">33348276</pub-id>
</element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><person-group>
<name><surname>Page</surname><given-names>MJ</given-names></name>
<name><surname>McKenzie</surname><given-names>JE</given-names></name>
<name><surname>Bossuyt</surname><given-names>PM</given-names></name>
<etal/>
</person-group><fpage>0</fpage><volume>372</volume><year>2021</year></element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Potential drug-drug interactions in hospitalized cancer patients: a report from the Middle-East</article-title><source>J Oncol Pharm Pract</source><person-group>
<name><surname>Moghaddas</surname><given-names>A</given-names></name>
<name><surname>Adib-Majlesi</surname><given-names>M</given-names></name>
<name><surname>Sabzghabaee</surname><given-names>AM</given-names></name>
<name><surname>Hajigholami</surname><given-names>A</given-names></name>
<name><surname>Riechelmann</surname><given-names>R</given-names></name>
</person-group><fpage>46</fpage><lpage>53</lpage><volume>27</volume><year>2021</year><pub-id pub-id-type="pmid">32183585</pub-id>
</element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>Potential drug interactions in elderly cancer patients</article-title><source>Crit Rev Oncol Hematol</source><person-group>
<name><surname>Girre</surname><given-names>V</given-names></name>
<name><surname>Arkoub</surname><given-names>H</given-names></name>
<name><surname>Puts</surname><given-names>MT</given-names></name>
<name><surname>Vantelon</surname><given-names>C</given-names></name>
<name><surname>Blanchard</surname><given-names>F</given-names></name>
<name><surname>Droz</surname><given-names>JP</given-names></name>
<name><surname>Mignot</surname><given-names>L</given-names></name>
</person-group><fpage>220</fpage><lpage>226</lpage><volume>78</volume><year>2011</year><pub-id pub-id-type="pmid">20594867</pub-id>
</element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment</article-title><source>Oncologist</source><person-group>
<name><surname>Ramsdale</surname><given-names>E</given-names></name>
<name><surname>Mohamed</surname><given-names>M</given-names></name>
<name><surname>Yu</surname><given-names>V</given-names></name>
<etal/>
</person-group><fpage>0</fpage><lpage>8</lpage><volume>27</volume><year>2022</year></element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>Polypharmacy and reversible drug induced QT prolongation in a patient with advanced cancer: case report</article-title><source>J Pain Palliat Care Pharmacother</source><person-group>
<name><surname>Cerd&#x000e0;</surname><given-names>G</given-names></name>
<name><surname>Juli&#x000e0;-Torras</surname><given-names>J</given-names></name>
<name><surname>Gonz&#x000e1;lez-Barboteo</surname><given-names>J</given-names></name>
<name><surname>Romeo</surname><given-names>M</given-names></name>
<name><surname>Calsina-Berna</surname><given-names>A</given-names></name>
</person-group><fpage>33</fpage><lpage>37</lpage><volume>38</volume><year>2024</year><pub-id pub-id-type="pmid">38180376</pub-id>
</element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Atrial fibrillation and QT prolongation due to proton pump inhibitor-induced hypomagnesemia</article-title><source>Ann Cardiol Angeiol (Paris)</source><person-group>
<name><surname>Noirclerc</surname><given-names>N</given-names></name>
<name><surname>Delfanne</surname><given-names>C</given-names></name>
<name><surname>Dompnier</surname><given-names>A</given-names></name>
</person-group><fpage>201</fpage><lpage>203</lpage><volume>69</volume><year>2020</year><pub-id pub-id-type="pmid">32800318</pub-id>
</element-citation></ref><ref id="REF28"><label>28</label><element-citation publication-type="journal"><article-title>Torsades de Pointes after ondansetron infusion in 2 patients</article-title><source>Tex Heart Inst J</source><person-group>
<name><surname>Lee</surname><given-names>DY</given-names></name>
<name><surname>Trinh</surname><given-names>T</given-names></name>
<name><surname>Roy</surname><given-names>SK</given-names></name>
</person-group><fpage>366</fpage><lpage>369</lpage><volume>44</volume><year>2017</year><pub-id pub-id-type="pmid">29259513</pub-id>
</element-citation></ref><ref id="REF29"><label>29</label><element-citation publication-type="webpage"><article-title>Management of QT Prolongation Risk in Cancer Patients</article-title><date-in-citation content-type="access-date">
<month>7</month>
<year>2024</year>
</date-in-citation><year>2018</year><uri xlink:href="https://journals.lww.com/oncology-times/fulltext/2018/01200/management_of_qt_prolongation_risk_in_cancer.2.aspx">https://journals.lww.com/oncology-times/fulltext/2018/01200/management_of_qt_prolongation_risk_in_cancer.2.aspx</uri></element-citation></ref></ref-list></back></article>